CoChat

Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Objective Clozapine is a unique atypical antipsychotic with superior efficacy in treatment-resistant schizophrenia. Plasma concentration of clozapine and its major metabolite N-desmethylclozapine (NDMC) as well as the ratio of NDMC to clozapine have been reported to be predictors of clozapine response. Here we evaluate these as well as other measures in an effort to find predictors of response to clozapine in our early-onset treatment-refractory population. Method Fifty-four children and adolescents participated in double-blind (n = 22) or open-label (n = 32) clozapine trials. Clinical evaluations took place at baseline, week 6 on clozapine, and at 2- to 6-year follow-up. The data were analyzed in relation to demographics, age at onset, IQ, clozapine dose, and plasma concentrations of prolactin, clozapine, NDMC, and NDMC/clozapine ratio. Stepwise regression and correlation analyses were performed to find predictors of treatment response. Results Clinical improvement after 6 weeks of clozapine treatment, as measured by the percentage of improvement on the Brief Psychiatric Rating Scale and the Scale for the Assessment of Positive Symptoms, was strongly associated with the NDMC/clozapine ratio at the 6-week time point (Pearson correlation coefficient: r = 0.41; p Conclusions The NDMC/clozapine ratio may be a valuable predictor of response to clozapine and may suggest new approaches to clozapine treatment.

Overview

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e31812eed10

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Perry, 1991, Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients, Am J Psychiatry, 148, 231

Cited by

See all 107

Metadata

Authors
SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., RAPOPORT, J. L., & GOGTAY, N.
Affiliations
Guy's Hospital (GB)
Corresponding author
SPORN, ALEXANDRA L.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2007-10
Volume
46
Issue
10
Pages
1349-1356
ISSN
0890-8567 (ISSN-L)
OpenAlex
W1966602005
Cited by
107
References
53
Citations by year
2026: 4 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 10 · 2012: 8
FWCI
4.03
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
clozapine, childhood schizophrenia, treatment-resistant schizophrenia, N-desmethylclozapine, predictors of treatment response, plasma drug concentration, adverse effects, long-term outcomes, atypical antipsychotics, children and adolescents
MeSH terms
Adolescent, Child, Clozapine, Double-Blind Method, Drug Therapy, Female, Humans, Male, Brief Psychiatric Rating Scale, Schizophrenia, Childhood, Time Factors, Antipsychotic Agents, Treatment Outcome, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. https://app.cochat.ai/papers/10.1097/chi.0b013e31812eed10
The paper
SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., RAPOPORT, J. L., & GOGTAY, N. (2007). Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e31812eed10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.